Last reviewed · How we verify
NCT06409832: RAISE
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)
trial testing Rimegepant 75 mg in Migraine in 100 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | University of Florence |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 26 March 2024 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 September 2027 |
| Sites | 2 locations across Italy |
Drugs / interventions tested
- Rimegepant 75 mg (rimegepant-75-mg) — full drug profile →
Conditions studied
- Migraine — all drugs for Migraine →
- Migraine With Aura — all drugs for Migraine With Aura →
- Migraine Without Aura — all drugs for Migraine Without Aura →
- Chronic Migraine — all drugs for Chronic Migraine →
Sponsor
University of Florence
Who can join
18 and older, any sex, with Migraine or Migraine With Aura. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Changes in migraine frequency after three months of treatment
Time frame: Baseline (T0) - 3 months of treatment with rimegepant (T3)
Changes in monthly migraine days after three months of treatment with rimegepant compared to baseline (continuous variable) -
Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with rimegepant
Time frame: Baseline (T0) - 3 months of treatment with rimegepant (T3)
Percentage of 50% Responders (namely patients who presented a reduction of MMDs \>/ = 50% compared to baseline) after three months of treatment with rimegepant
Sponsor's own description
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06409832
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine
Currently open trials in the same condition.
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting
Other University of Florence trials
Trials by the same sponsor.
- NCT06628921 — The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) · recruiting
- NCT06123000 — Modified Widman Flap vs Fibre Retention Osseous Resective Surgery · NA · recruiting
- NCT06135753 — Psychosomatic Intervention in Fibromyalgia. · NA · recruiting
- NCT06086821 — Clinical Relevance of Different Time of Periodontal Re-evaluation · NA · completed
- NCT06884553 — Robotic Rehabilitation Vs Occupational Therapy Chronic Stroke Upper Limb Rehabilitation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06409832 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florence
- Last refreshed: 19 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06409832.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing